Venlafaxine ER Long-Term Extension Study for Major Depressive Disorder (MDD)

PHASE3CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Major Depressive Disorder
Interventions
DRUG

Venlafaxine ER

Treatment phase: 10 months (75-225 mg/day), oral administration Tapering phase: 1-3 weeks (stepwise dose reduction: 150-37.5 mg/day), oral administration

Trial Locations (25)

270-1694

Nippon Medical School Chiba Hokusoh Hospital, Inzai

278-0033

Nakamoto Clinic, Noda

810-0041

Stress Care Yoshimura Clinic, Fukuoka

Stress Care Yoshimura Clinic, Fukuoka

802-0064

Hatakeyama Clinic, Kitakyushu

836-0004

Shiranui Hospital, Omuta

738-0023

Fujikawa Clinic, Hatsukaichi

659-0093

Takahashi Psychiatric Clinic, Ashiya

655-0037

Ikeuchi Psycho Induced Internal Med.Clinic, Kobe

920-8650

National Hospital Organization Kanazawa Medical Center, Kanazawa

214-0014

Medical Corporation Seishinkai Kishiro Mental Clinic, Kawasaki

252-0303

Yutaka Clinic, Sagamihara-shi

221-0835

Tawara Clinic, Yokohama

Medical Corporation Toyokokai Tawara Clinic, Kanagawa

238-0042

Shioiri Mental Clinic, Yokosuka

589-0011

Shibamoto Clinic, Osakasayama-shi

120-0033

Suzuki Hospital, Adachi-ku

154-0004

Sangenjaya Nakamura Mental Clinic, Setagaya-ku

150-0001

Omotesando Mental Clinic, Shibuya-ku

151-0053

Maynds Tower Mental Clinic, Shibuya-ku

162-8543

Tokyo Kosei Nenkin Hospital, Shinjuku-ku

170-0002

Himorogi Psychiatric Institute, Toshima-ku

810-0004

Tenjin Mental Clinic, Fukuoka

810-0801

Kuranari Psychiatry Clinic, Fukuoka

616-8421

Sagaarashiyama-Tanaka Clinic, Kyoto

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT01485887 - Venlafaxine ER Long-Term Extension Study for Major Depressive Disorder (MDD) | Biotech Hunter | Biotech Hunter